Physician profile
Lan Nguyen
NPI 1174516264
$2,921.62
in general payments reported to CMS, 2019-2025
21 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $866 · 2020: $101 · 2021: $204 · 2022: $402 · 2023: $618 · 2024: $414 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $988 · Long Term Medical Supply Or Device Loan: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $987.72 |
| Long Term Medical Supply Or Device Loan | $360.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $732.67 | 2019-2025 | Rocklatan, Wavelight Refractive Suite, Hydrus Microstent |
| Carl Zeiss Meditec USA, INC. | $383.58 | 2021-2023 | Lumera 700 |
| Aerie Pharmaceuticals, INC. | $313.92 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $191.50 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $188.23 | 2019-2022 | |
| Oyster Point Pharma, INC. | $160.19 | 2022-2024 | Tyrvaya |
| Glaukos Corporation | $109.79 | 2022-2025 | Iaccess Precision Blade, Istent Infinite Trabecular Micro-Bypass System Model Is3, Istent Inject Trabecular Micro-Bypass System Model G2-M-Is |
| Nx Development Corp. | $109.25 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $109.19 | 2019-2021 | |
| Abbvie INC. | $92.47 | 2024-2025 | |
| Bausch & Lomb Americas INC. | $90.21 | 2022-2023 | Prolensa, Lotemax Sm, Alrex |
| Allergan, INC. | $80.09 | 2019-2020 | |
| Revance Therapeutics, INC. | $80.00 | 2024 | Daxxify |
| Akorn, INC. | $71.99 | 2019 | |
| Thea Pharma INC. | $41.62 | 2024-2025 | Iyuzeh |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $39.05 | 2019 | |
| Dexcom, INC. | $36.80 | 2022 | |
| Boston Scientific Corporation | $31.25 | 2021 | |
| Horizon Therapeutics Plc | $23.24 | 2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $18.68 | 2024 | Xdemvy |
| Harrow Eye, LLC | $17.90 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lan Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.